oncolytic adenovirus AdAPT-001

A replication competent human attenuated adenoviral vector, TAV-255, modified to express a human transforming growth factor beta (TGF-b) trap fusion protein that neutralizes TGF-b, with potential oncolytic, immunomodulating and antineoplastic activities. Upon administration, oncolytic adenovirus AdAPT-001 selectively binds to and replicates in tumor cells and induces tumor cell lysis. In addition, tumor cell lysis releases a variety of tumor-associated antigens (TAAs) which may potentially result in the activation of a systemic immune response against the TAAs-expresssing tumor cells. AdAPT-001 has been attenuated to prevent replication in healthy cells.